Browsing by author "Dowsett, Mitch"
Now showing items 41-50 of 50
-
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
Brentnall, AR; Cuzick, J; Byers, H; Segal, C; Reuter, C; et al. (2016-08)A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict ... -
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Heindl, A; Sestak, I; Naidoo, K; Cuzick, J; Dowsett, M; et al. (2018-02)Background Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor-negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well ... -
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Sestak, I; Dowsett, M; Ferree, S; Baehner, FL; Cuzick, J (2016-08)Clinical variables and several gene signature profiles have been investigated for the prediction of (distant) recurrence in several trials. These molecular markers are significantly correlated with overall and late distant ... -
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Acs, B; Leung, SCY; Kidwell, KM; Arun, I; Augulis, R; et al. (Springer Science and Business Media LLC, 2022-06-21)Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image analysis (DIA) platform ... -
Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
Dowsett, M (American Society of Clinical Oncology (ASCO), 2022-04-12) -
The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith, OL; Spies, NC; Anurag, M; Griffith, M; Luo, J; et al. (2018-09-04)Here we report targeted sequencing of 83 genes using DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) hormone receptor-positive (HR+) patients to determine ... -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Dowling, RJO; Kalinsky, K; Hayes, DF; Bidard, F-C; Cescon, DW; et al. (2019-12)Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor-positive breast cancer patients. Many of these recurrences occur late, more than 5 years after original ... -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Dowling, RJO; Sparano, JA; Goodwin, PJ; Bidard, F-C; Cescon, DW; et al. (2019-12)Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened ... -
TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial
Filipits, M; Gnant, M; Dafni, U; Polydoropoulou, V; Hills, MJ; et al. (AMER ASSOC CANCER RESEARCH, 2015-05-01) -
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick, J; Sestak, I; Forbes, JF; Dowsett, M; Cawthorn, S; et al. (2020-01)BACKGROUND:Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer ...